Arcturus Therapeutics (ARCT) announced the initiation of the company’s Phase 1 study of ARCT-2304, a self-amplifying mRNA vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.